Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

ResMed (ASX:RMD) Falls — What Is Behind the Medical Device Giant’s Session Decline?

Resmed Inc (ASX:RMD) fell to $27.78, recording a session decline of -2.90%. ResMed is among the ASX’s largest healthcare names by market capitalisation, and any session fall of this scale can reflect movements in its primary US listing as much as ASX-specific conditions.

Sonal Goyal | 15 July 2026

Clinuvel Pharmaceuticals (ASX:CUV) Falls — What Is Pulling Rare Disease Biotech Lower?

Clinuvel Pharmaceuticals fell to $9.95, recording a session decline of -2.36%. Clinuvel is unusual among ASX biotechnology companies in being consistently profitable, and the session decline draws attention to whether clinical, regulatory or broader healthcare sector factors are influencing the move.

Sonal Goyal | 15 July 2026

Starpharma (ASX:SPL) Launches $32 Million Fully Underwritten Entitlement Offer to Advance Oncology Pipeline

The announcement accompanies a period of increased investor attention on Starpharma’s dendrimer technology platform following disclosures about its potential applications in radioligand therapy across multiple oncology targets.

Sonal Goyal | 15 July 2026

4DMedical (ASX: 4DX) Drops 4.03% as Healthcare Investors Reassess Risk

4DMedical Limited (ASX:4DX) shares came under pressure on Tuesday, 14 July 2026, as the lung-imaging technology company continued a period of significant share-price volatility.

Aditi Sarkar | 14 July 2026

Medibank Private (ASX:MPL) Consolidates Near Highs — What Is the Private Health Insurance Giant’s Outlook?

Medibank Private Ltd eased to $5.05 on 14 July 2026 and has declined approximately 0.20% over the past twelve months, placing it near the upper end of its twelve-month trading range.

Sonal Goyal | 14 July 2026

Starpharma (ASX:SPL) Up 662% in a Year — The Biotech Near Its High That Has the Market Talking

Starpharma Holdings Ltd moved higher to $0.755 on 14 July 2026 and has gained approximately 662.63% over the past twelve months, placing it near the upper end of its twelve-month trading range.

Sonal Goyal | 14 July 2026

Recce Pharmaceuticals (ASX:RCE) Expands Global Patent Footprint for Its Anti-Infective Drug Platform

On 14 July 2026 that portfolio grew again. Recce said it had secured a patent in Vietnam covering its anti-infective compounds, extending protection for its drug candidates through 2041. It described the grant as its eighth Family 4 patent, adding to protections already in …

Sonal Goyal | 14 July 2026

Recce Pharmaceuticals (ASX:RCE) Extends Drug Patent Protection to 2041 With Vietnam Approval

The grant covers RECCE 327 and RECCE 529, including their development and use in treating bacterial and viral infections across multiple delivery methods. It is the company’s eighth patent within what Recce calls its Family 4 group, joining protections already held in markets such …

Sonal Goyal | 14 July 2026

PYC Therapeutics (ASX:PYC) Eases While Holding on to Positive One-Year Returns

PYC Therapeutics Ltd (ASX:PYC) finished Tuesday's trading session lower, with its shares closing at AUD 1.52 on 14 July 2026, down 2.26%, or AUD 0.035, for the day. Despite the decline, the biotechnology company continues to trade above its level from a year ago, …

Aditi Sarkar | 14 July 2026

Can Regis Healthcare (ASX:REG) Regain Momentum? Here's What Investors Are Watching

Regis Healthcare Ltd (ASX:REG) was under modest selling pressure during the afternoon trading session on 14 July 2026, with its shares trading at AUD 6.05, down 1.79%, or AUD 0.11, for the day. Despite the latest decline, the stock remained down 17.01% over the …

Aditi Sarkar | 14 July 2026
Support

Hi! How can we help you today?

Loading…